CMS approves off-label chemotherapy compendium
Executive SummaryCMS will recognize the National Comprehensive Cancer Network Drugs & Biologics Compendium as an approved reference for coverage of off-label uses of cancer drugs and biologics, the agency announces June 5. Local Medicare contractors who process claims for Part B, or physician-administered, drugs would consult the compendia when deciding whether to approve claims. CMS also announces it will formally delete from its list of recognized compendia the American Medical Association Drug Evaluations compendium, which ceased publication in 1996. The decisions represent a first step in CMS' efforts to update its compendia list; decisions in the coming weeks are expected on three other references - Gold Standard's Clinical Pharmacology and Thomson Micromedex's DrugPoints and DrugDex (1"The Pink Sheet" April 14, 2008, p. 15)
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.